Cybrexa Therapeutics

Biotechnology ResearchConnecticut, United States11-50 Employees

Cybrexa is a clinical-stage oncology biotechnology company developing novel antigen-independent peptide drug conjugates (ADCs) aimed at combatting a range of cancer types, including ovarian, breast and non-small cell lung cancer. With the potential to disrupt the standard of care, the Cybrexa alphalex™ technology is a novel antigen-independent peptide drug conjugate (PDC) platform that enables targeted delivery of highly potent anticancer treatments and aims to revolutionize the standard of care in oncology. The platform consists of a pHLIP® peptide, linker, and small molecule anti-cancer agent. pHLIP® peptides are a family of pH-Low Insertion Peptides that target acidic cell surfaces. pHLIP® was developed at Yale University and the University of Rhode Island, and is exclusively licensed to pHLIP, Inc. alphalex™ represents the disruptive next generation in tumor targeting. Early clinical trials of the company’s lead candidate, CBX-12, demonstrate robust efficacy signals and tolerability in patients with metastatic cancer.  

As a privately held company, Cybrexa is led by a management team experienced at building life science companies and driven by scientists with an expertise in drug development and oncology.

For more information, visit www.cybrexa.com.  
Community Guidelines: https://bit.ly/3GI6AU0

Sign up for free to view info

Email Format Employee directory